Latest Security News

Hutchison Telecommunications (Amsterdam) B.V. has announced an off-market takeover bid for the 12.13% of Hutchison Telecommunications (Australia) Limited shares it does not already own, offering a 52.4% premium. The move aims to consolidate full ownership of the Australian telecom operator.

Dexus has successfully secured a court injunction preventing Australia Pacific Airports Corporation from suspending its shareholder rights, buying time ahead of a key legal battle in August.

Comms Group Ltd launches a $7 million capital raising, including a fully underwritten entitlement offer, to acquire Tasmanian IT services provider TasmaNet, aiming to boost its revenue and market reach significantly.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Solstice Minerals has pinpointed promising mineral resource extension targets at its Nanadie Copper-Gold Project in Western Australia, setting the stage for a potential significant increase in copper and gold resources.

Arika Resources has identified 10 significant new gold targets at its Ithaca Prospect near Genesis Minerals’ Ulysses-Orient Well operation, setting the stage for upcoming drill testing at the Kookynie Gold Project.

Stavely Minerals is set to restart reverse circulation drilling at its Fairview gold prospect in Western Victoria, aiming to validate a major mineralised structure linked to high-grade copper-silver zones nearby. This move reflects a strategic pivot towards gold exploration in response to soaring gold prices.

New Frontier Minerals advances its NWQ Copper Project by securing bulk sample processing at Austral Resources’ Mt Kelly plant, accelerating its path to copper production in Queensland’s Mt Isa Copper Belt.

Australian Agricultural Company Limited (AACo) reported a robust FY25 operating profit of $58.4 million, driven by increased meat and cattle sales volumes and strategic brand growth despite inflationary pressures.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

Elixinol Wellness Limited is poised to lift its trading suspension on May 22, 2025, following a significant announcement regarding its financing and capital structure.